487 filings
Page 3 of 25
6-K
pdecv2 nrsv1ae
15 Jun 23
Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome
4:30pm
EFFECT
fnp2vmsccik0 xjpq3m
12 Jun 23
Notice of effectiveness
12:15am
EFFECT
fr3g9chz202c6g6f
12 Jun 23
Notice of effectiveness
12:15am
424B3
kcdka
9 Jun 23
Prospectus supplement
4:36pm
424B3
815mj8ca9n9
9 Jun 23
Prospectus supplement
4:35pm
CORRESP
9mwwgp3l
9 Jun 23
Correspondence with SEC
12:00am
CORRESP
q5z27n
9 Jun 23
Correspondence with SEC
12:00am
UPLOAD
7wtx0 sw5zzoe
8 Jun 23
Letter from SEC
12:00am
UPLOAD
aiubm9
8 Jun 23
Letter from SEC
12:00am
F-3
xkei7hg0g75olwq
1 Jun 23
Shelf registration (foreign)
4:35pm
F-1
wmk9f 5p1w
1 Jun 23
Registration statement (foreign)
4:31pm
6-K
ipv239rj5kvx 5a2siv8
30 May 23
Notice of the Annual General Meeting of Shareholders
8:00am
6-K
m7a04frk4q3 ja
26 May 23
Report of Foreign Private Issuer
5:29pm
6-K
bnwi5fc w5be
16 May 23
Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results
4:30pm
6-K
261uc215sqbe s5sm9
2 May 23
Convertible Loan Agreement
8:30am
NT 20-F
2ilb nqvf
1 May 23
Notice of late annual filing (foreign)
4:59pm
SC 13D/A
t513axx
27 Apr 23
Altamira Therapeutics / Meyer Thomas ownership change
4:30pm
6-K
jpcayumttq7rmp6r6of
18 Apr 23
Report of Foreign Private Issuer
8:00am
CERT
a4s7jtj
17 Apr 23
Certification of approval for exchange listing
12:21pm